So the EIK1003-001, this is the phase one part we’re going to present. The main results, the main takeaway is that the selective PARP1 inhibitors are safe and efficacious both in monotherapy and in particular in combination therapy with weekly paclitaxel. So this would be for the combination therapy, which I think we should focus the most on, where we combined the selective PARP1 inhibitors with weekly paclitaxel, showed encouraging safety results and also an objective response rate of 24% in heavily pretreated cancer patients with breast and ovarian cancer...
So the EIK1003-001, this is the phase one part we’re going to present. The main results, the main takeaway is that the selective PARP1 inhibitors are safe and efficacious both in monotherapy and in particular in combination therapy with weekly paclitaxel. So this would be for the combination therapy, which I think we should focus the most on, where we combined the selective PARP1 inhibitors with weekly paclitaxel, showed encouraging safety results and also an objective response rate of 24% in heavily pretreated cancer patients with breast and ovarian cancer.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
